Biotech Values

[DewDiligence]

Based on today's dataset, AKRO is seeking to resuscitate the failed phase-2 trial in cirrhotic NASH:

https://www.fiercebiotech.com/biotech/akero-bruised-earlier-failure-soars-liver-scarring-improves-longer-mash-trial

The deepening responses seen between Week 24 and Week 96 bode well for the Akero study that failed last year. At the time, Akero argued showing a statistically significant improvement in fibrosis by Week 36 was a “high bar.” The biotech is tracking participants in the failed trial through Week 96, suggesting it may reverse the failure at a later readout if responses improve over time. Results are due next year.